EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Deni Study: Real‐World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group

Pierre Kubicek, Catherine Guérin‐Charbonnel, Maud Toulmonde, Pascaline Boudou‐Rouquette, Valentin Thibaud, Nicolas Penel, Antoine Italiano, Thomas Ryckewaert, Nelly Firmin, François Bertucci, Armelle Dufresne, Patrick Soulié, Christophe Perrin, Sabine Noal, Mehdi Brahmi, Jean‐Yves Blay, Emmanuelle Bompas

International Journal of Cancer · 2027-01-01 · 160 (1) · 161-170

DOI: 10.1002/ijc.70672 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT The DeFi trial revealed a significant improvement in progression‐free survival (PFS) with nirogacestat in patients with desmoid tumors. The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real‐world study. Outcomes included objective response, pain improvement, 1‐year PFS, and toxicity. Between February and June 2024, 55 patients with desmoid tumors were included (37 women). Data were updated until November 2025. The median age was 38.6 years (range: 18.0–66.7). The median number of previous therapies was 2, including local therapies. The median follow‐up was 21.4 months [95% CI: 19.5; 25.6]. The estimated median duration of nirogacestat treatment was 16 months. Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1‐year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions. Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics. The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension. The DeNi study confirms the clinical benefits of nirogacestat in patients with desmoid tumors, with improvements in pain and tumor shrinkage observed in 60% of patients and PFS consistent with that reported in the phase III DeFi trial.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →